EUVIMEDEUVIMED entdecken
Crossref

Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto, Shinsuke Mizoguchi, Takayuki Nakayama, Hironori Fukuda, Hiroaki Shimmura, Yasunobu Hashimoto, Kazuhiko Yoshida, Junpei Iizuka, Kenji Omae, Tsunenori Kondo und 1 weitere

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Hiroki Ishihara und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Saiseikai Kawaguchi General Hospital, 5-11-5 Nishikawaguchi, Kawaguchi, Saitama, Japan. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell, Ipilimumab, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data regarding long-term outcomes of nivolumab plus ipilimumab for previously untreated advanced renal cell carcinoma (RCC) in real-world patients are limited.

Methods

This retrospective study evaluated clinical data of 66 patients who received nivolumab plus ipilimumab with a minimum 4-years follow-up. Effectiveness and prognosis following deferred cytoreductive nephrectomy (CN) and treatment-free interval (TFI), as well as safety profiles, were assessed.

Results

During the follow-up (median 39.7 months), 54 (82%) and 29 (44%) patients had disease progression and died, respectively. Median progression-free survival and overall survival (OS) were 8.98 and 62.1 months, respectively. Objective response was observed in 32 patients (48%), and the median duration of response was 21.1 months. Deferred CN was conducted in seven patients (11%), and the 3-year OS rate after deferred CN was 86%. TFI for at least 6 months was obtained in 13 patients (20%), with a 3-year OS rate after treatment-off was 92%. Grade ≥ 3 adverse events occurred in 29 patients (44%), and 11 patients (17%) required high-dose glucocorticoids (≥40 mg of prednisone/day).

Conclusion

Long-term follow-up data showed a feasible effectiveness and safety profile of nivolumab plus ipilimumab for real-world patients with advanced RCC. Although prognosis following deferred CN and TFI appeared favorable, prospective randomized trials are needed to confirm survival benefit of deferred CN and TFI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Renal CellIpilimumabKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesFollow-Up StudiesAdultAged, 80 and overTreatment OutcomeSurvival Rate

Stichwörter der Autor:innen

IO-IOIO-TKIadverse eventdurable responseimmune checkpoint inhibitorimmunotherapy

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Department of Urology, Saiseikai Kawaguchi General Hospital, 5-11-5 Nishikawaguchi, Kawaguchi, Saitama, Japan.
  • Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan.
  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, 4-33-1 Kouhoku, Adachi-ku, Tokyo, Japan.
  • Department of Urology, Jyoban Hospital, Uenodai 57, Joban Kamiyunagayamachi, Iwaki, Fukushima, Japan.
  • Department of Urology, Saiseikai Kazo Hospital, 1680 Kamitakayanagi, Kazo, Saitama, Japan.
  • Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, Japan.

Zitieren

APA

Ishihara, H., Nishimura, K., Nemoto, Y., Mizoguchi, S., Nakayama, T., Fukuda, H., Shimmura, H., Hashimoto, Y., Yoshida, K., Iizuka, J., Omae, K., Kondo, T., & Takagi, T. (2025). Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf093

Vancouver

Ishihara H, Nishimura K, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, et al. Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf093

BibTeX
@article{Ishihara2025,
  author = {Ishihara, Hiroki and Nishimura, Koichi and Nemoto, Yuki and Mizoguchi, Shinsuke and Nakayama, Takayuki and Fukuda, Hironori and Shimmura, Hiroaki and Hashimoto, Yasunobu and Yoshida, Kazuhiko and Iizuka, Junpei and Omae, Kenji and Kondo, Tsunenori and Takagi, Toshio},
  title = {Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf093}
}
Kostenlos starten →